Amgen(AMGN)

THOUSAND OAKS, CABiotechnology3 H-1B visas (FY2023)

View 1,826 open jobs Website LinkedIn Careers Page

Focus: Amgen is a $28.2B revenue, California-based biotechnology leader focused on small molecules and biologics across oncology, cardiovascular, bone health, immunology, and neuroscience. With 27,000 employees and a 44-year history as a public company, it ranks among the world's largest independent biotech firms.

Oncology Cardiovascular Bone Health Immunology

Profile data last refreshed 16h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

27,000

Open Jobs

1826+2866 this month

Hot — 3701 jobs added in 30d

Net +2866 (3701 new, 835 removed). Aggressive expansion phase.

2 recent layoff filings (12 mo) — 100 affected

3/26/2026 — Medford, OR · 78 affected · Layoff
3/9/2026 — 9605 Medical Center Drive, Suite 325 Rockville, MD 20850, MD · 22 affected · Layoff

Source: state DOL filings via Big Local News

Should You Work at Amgen?

AI assessment

Amgen offers strong financial stability and career depth for established biotech professionals, but revenue concentration and recent operational headwinds warrant careful evaluation of role stability and team tenure.

Why Work Here

Access to a mature, diversified pipeline with 30+ active programs spanning Phase 1–approved stages and exposure to cutting-edge modalities (mAbs, bispecific antibodies, gene therapy vectors).

Data completeness

7/9 — Strong

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

3 imminent

CORLANOR

Hiring

Stable

Revenue

$28.2B

FY2025

Key Products

PROLIA

RANK Ligand Inhibitor

$673M Part D

LOE Approaching

Amgen's anchor product representing 44% of total revenue; approaching loss of exclusivity creates significant downstream commercial and R&D restructuring risk.

Help build intelligence for Amgen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

teprotumumab

Thyroid Eye Disease

APPROVED_FOR_MARKETING

Clinical Trials (5)

NCT03461211Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Phase 3

NCT01868997Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Phase 2

NCT06674941A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

Phase 1

+2 more

carfilzomib

Multiple Myeloma

APPROVED_FOR_MARKETING

Clinical Trials (5)

NCT03934684Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4

NCT01568866Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Anemia

N/A

Clinical Trials (1)

NCT01444456Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

N/A

trifluridine

Mycobacterium Avium-Intracellulare Infection

N/A

Clinical Trials (3)

NCT05198934Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Phase 3

NCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy

Enbrel®

Rheumatoid Arthritis

N/A

Clinical Trials (1)

NCT00121056REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations

N/A

AI-Detected CAC Notification and Care Facilitation

Atherosclerotic Cardiovascular Disease (ASCVD)

N/A

Clinical Trials (1)

NCT07355894Health Enhanced Artery Risk Tracking With Widespread Implementation and Screening Effort in ASCVD (HEARTWISE-ASCVD)

N/A

Health Economy Register

Breast Neoplasms

N/A

Clinical Trials (1)

NCT04386629Health Economy Register

N/A

Any treatment for unresectable HCC as chosen by the physician

Carcinoma, Hepatocellular

N/A

Otago Exercise Program

Hip Fractures

N/A

Clinical Trials (1)

NCT04748354Reducing Fall Risk Post Hip Fracture in Mild Cognitive Impairment

N/A

interferon gamma-1b

HIV Infections

N/A

Clinical Trials (2)

NCT06529731Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

NCT00002433The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS

Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During

Chemotherapy-induced Febrile Neutropenia

N/A

Clinical Trials (1)

NCT01813721Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.

N/A

Observations

Anemia

N/A

Clinical Trials (1)

NCT00727571LEARN-6™: A Prospective, Observational Nursing Home Study

N/A

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Car

Major Cardiovascular Event

N/A

Clinical Trials (1)

NCT06295679A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

N/A

a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterol

Familial Hypercholesterolemia

N/A

Clinical Trials (1)

NCT03398954a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia

N/A

Pharmacological education

Fracture of Femur

N/A

Clinical Trials (1)

NCT05669040mHealth to Improve the Experience, Adherence to Drug Treatment and Positive Mental Health

N/A

Retrospective Chart Review

Idiopathic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT00454857Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

N/A

standard care

Hyperparathyroidism, Secondary

N/A

Clinical Trials (3)

NCT01196715Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes

Phase 3

NCT05601492Adherence to Otezla

Phase 1

National Register of Actionable Mutations

Solid Tumours in Advanced Stages

N/A

Care Champion Intervention

ASCVD

N/A

Clinical Trials (1)

NCT06471036Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?

N/A

Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

Cancer

N/A

Clinical Trials (1)

NCT00300001Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes

N/A

Osteonecrosis of the Jaw (ONJ) Case Registry

Osteonecrosis of the Jaw

N/A

Clinical Trials (1)

NCT01666106Osteonecrosis of the Jaw (ONJ) Case Registry

N/A

talimogene laherparepvec

Melanoma

N/A

Clinical Trials (5)

NCT00769704Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Phase 3

NCT01161498Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Lung Cancer

N/A

Care Transitions in Renal Disease Patients

Renal Disease

N/A

Clinical Trials (1)

NCT01842776Care Transitions in Renal Disease Patients

N/A

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients

Cystic Fibrosis

N/A

Aranesp

Chronic Kidney Disease, Receiving Dialysis

N/A

Clinical Trials (5)

NCT00117117A Study to Assess Symptom Burden in Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Phase 4

NCT00117065Study of Transplant Related Anemia Treated With Aranesp® (STRATA)

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pat

Metastatic Colorectal Cancer

N/A

Clinical Trials (1)

NCT02322736Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR

N/A

Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthr

Psoriatic Arthritis

N/A

Clinical Trials (1)

NCT01139918Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis

N/A

No Intervention for Observational Study

Idiopathic Thrombocytopenic Purpura

N/A

Clinical Trials (1)

NCT00861224Effects of Long-term Dosing of AMG 531 on Bone Marrow Morphology

N/A

MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)

Familial Hypercholesterolemia - Heterozygous

N/A

Clinical Trials (1)

NCT02517944MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)

N/A

Not applicable- observational study

Birth Defect

N/A

Clinical Trials (1)

NCT02090088Nplate® Pregnancy Exposure Registry

N/A

MRI

Neuromyelitis Optica Spectrum Disorders

N/A

Clinical Trials (5)

NCT03783026A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis

Phase 4

NCT03182699Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients

Healing Circuits™ sessions

Crohn Disease (CD)

N/A

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Managem

Medical Conditions to be Studied

N/A

Clinical Trials (1)

NCT02993120Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

N/A

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Stud

RAS Wild Type mCRC

N/A

Clinical Trials (1)

NCT02792478Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study

N/A

ActiveHip+ mobile application

Hip Fractures

N/A

Clinical Trials (1)

NCT04859309Activating Older People After a Hip Fracture

N/A

COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Pa

HIV Seropositivity

N/A

Clinical Trials (1)

NCT03139630COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients

N/A

nonmyeloablative stem cell transplant

Metastatic Solid Tumor

N/A

Clinical Trials (1)

NCT00997529Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors

N/A

therascreen® KRAS RGQ PCR Kit

Colo-rectal Cancer

N/A

Clinical Trials (1)

NCT05347745Therascreen® KRAS RGQ PCR Kit

N/A

A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Tra

Hyperparathyroidism

N/A

Clinical Trials (1)

NCT01163669A Prospective Cohort Study to Describe the Evolution of Persistent Hyperparathyroidism in Kidney Transplant Recipients

N/A

Diffusion Weighted Magnetic Resonance Imaging

Myeloma

N/A

Clinical Trials (1)

NCT03951220The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss

N/A

OFF in experimental arm

Pancreatic Cancer

N/A

Clinical Trials (1)

NCT00786058A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003

N/A

Corrie Lipids Digital Health Program

Cardiovascular Risk

N/A

Dental implant surgery

Missing Teeth

N/A

Clinical Trials (1)

NCT04741906Outcome of Dental Implant Therapy in Patients Treated With Antiresorptive Medication

N/A

Opportunistic screening for low BMD

Low Bone Density

N/A

Clinical Trials (1)

NCT05245851Clinical Deployment and Validation of Rho

N/A

The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvM

ASCVD

N/A

Clinical Trials (1)

NCT04197453The Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 Inhibitors (cvMOBIUS)

N/A

Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Post-Traumatic Headache

N/A

application

Secondary Prevention

N/A

Clinical Trials (2)

NCT03619993Patient Preference for Pegfilgrastim (Neulasta®) Application Forms

N/A

NCT05542719Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular

N/A

Physician Survey

Solid Tumours

N/A

Clinical Trials (1)

NCT01998607Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw

N/A

A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving F

Head and Neck Cancer

N/A

Interview Prep Quick Facts

Founded: 1980

Portfolio: 49 approved products, 163 clinical trials

Top TAs: Oncology, Immunology, Nephrology

H-1B (2023): 3 approvals

Publications: 135 in PubMed

SEC Filings: 2 available

Open Roles: 1826 active jobs

Portfolio Health

Growth7 (14%)

Peak17 (35%)

LOE Approaching16 (33%)

Post-LOE9 (18%)

49 total products

Therapeutic Area Focus

Oncology

22 marketed583 pipeline

Immunology

13 marketed187 pipeline

Nephrology

5 marketed84 pipeline

Hematology

5 marketed83 pipeline

Financials (FY2025)

Revenue

$28.2B7%

R&D Spend

$4.8B(17%)8%

Net Income

$6.7B

Hiring Trend

Actively Hiring

1826

Open Roles

+766

Added

-173

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Risk Signals

WARN Act Layoff Notices (2)

2026-03-26

78 employees affected— Medford, OR

2026-03-09

22 employees affected— Rockville, MD

Source: state DOL filings, aggregated via Big Local News

100 employees across Medford, OR (78) and Rockville, MD (22) in March 2026; reason listed as layoff, suggesting cost restructuring or facility consolidation.

Recent layoffs across manufacturing and non-manufacturing functions signal potential organizational restructuring; combined with cybersecurity breach (August 2026), near-term role stability warrants inquiry into specific team plans and leadership tenure.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Frontline therapies for adult patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a systematic literature review.

Hematology (Amsterdam, Netherlands)

2026

PMID:42711755

Treatment patterns of bone-targeted agents for the prevention of skeletal-related events in multiple myeloma in Bulgaria: a cross-sectional chart review study.

Amgen(AMGN)

Should You Work at Amgen?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (28)

Key Products by Revenue

Other Products (9)

Pipeline & Clinical Trials

Recent News · Amgen(10)

Open Jobs (1826)

Key Account Manager (Rare Disease) - Endocrinology-Ocular - Dallas

Job Posting Title Account Manager/Specialty Account Manager - TEPEZZA (Ocular) - San Diego, CA

Key Account Manager - Endocrinology-Ocular (Rare Disease) - Houston

Key Account Manager (Rare Disease) - Endocrinology-Ocular - Nashville

Rare Disease Key Account Manager - Neurology - Southern California

Account Manager/Specialty Account Manager - Tavneos - Fairfax, VA

Account Manager/Specialty Account Manager - Tavneos - Virginia, Beach

Account Manager/Specialty Account Manager -KRYSTEXXA (Rare Disease) - Providence, RI

Account Manager / Specialty Account Manager - UPLIZNA - Albuquerque, NM (Rare Disease), Neurology

Medical Science Liaison; U.S. Medical, Rare Disease-GPA/MPA & Sjögren’s Disease - VA/WV/E. KY

Medical Science Liaison - Rare Disease-GPA/MPA & Sjögren’s Disease - Arizona and New Mexico

Medical Science Liaison - Rare Disease-GPA/MPA & Sjögren’s Disease - Georgia

Medical Science Liaison - Rare Disease-GPA/MPA & Sjögren’s Disease - Central Florida

Senior Medical Science Liaison - Rare Disease-GPA/MPA & Sjögren’s Disease - San Jose, CA

Clean Utilities Sr Engineer

Senior CIP/SIP Process Engineer

Rare Disease Key Account Manager - Rheumatology-Nephrology - Southeast

Rare Disease Key Account Manager - Rheumatology-Nephrology - Southern California

Key Account Manager - Neurology (Rare Disease) - Northeast

Rare Disease Key Account Manager - Neurology - Mid South

Rare Disease Key Account Manager - Neurology - Southeast

Rare Disease Key Account Manager - Neurology - Mid-Atlantic

Key Account Manager - Endocrinology-Ocular (Rare Disease) - New York, Metro

Key Account Manager - Endocrinology-Ocular (Rare Disease) - Pacific Northwest

Senior Medical Science Liaison; U.S. Medical, Rare Disease-GPA/MPA & Sjögren’s Disease-Metro NY

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Risk Signals

WARN Act Layoff Notices (2)

Research Publications(10)